Newly published results (phase II) from the CATIE schizophrenia treatment efficacy study sponsored by the National Institute of Mental Health comparing the most commonly used second generation drug treatments for schizophrenia and depression, is highly disturbing.
“When Anita Louise Smith enrolled in an experimental drug trial in 2002 in Colorado, she had a diagnosis of multiple sclerosis but no symptoms and was looking to reduce the chances of being ravaged by the disease. Last year, she died at the age of 46 from an infection linked to the drug.”
"Now they are terrified that their crimes of commission and omission could reap them the same whirlwind harvest of accountability."
Former FDA Commissioner or Wife Held Stock in FDA Regulated Area – NYT Thu, 27 Oct 2005 The mystery behind the resignation of Dr. Lester Crawford seems to be about failure to divest from financail holdings in companies regualted by the FDA. The New York Times cites Dr. Crawford’s statement…
Bad Medicine: A Gift for Drug Makers–Malpractice Bill Shields Drugmakers Sat, 15 Jan 2005 Knowledgable critics – among them practicing physicians, health care analysts, medical journal editors, journalists, and lay citizens–have reached the conclusion that America’s for-profit health care system – which eats up 16% of the budget–has failed to…
